← Back to Screener
Palatin Technologies, Inc. (PTN)
Price$22.07
Favorite Metrics
Price vs S&P 500 (26W)197.52%
Price vs S&P 500 (4W)-0.95%
Market Capitalization$39.22M
All Metrics
Book Value / Share (Quarterly)$6.53
P/TBV (Annual)196.73x
Cash Flow / Share (Quarterly)$-9.04
Price vs S&P 500 (YTD)39.57%
Gross Margin (TTM)97.83%
Net Profit Margin (TTM)-28.85%
EPS (TTM)$-10.46
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-10.46
EPS (Annual)$-32.15
ROI (Annual)-9180.00%
Gross Margin (Annual)97.83%
Net Profit Margin (5Y Avg)-4465.01%
Cash / Share (Quarterly)$8.24
ROA (Last FY)-529.77%
Revenue Growth TTM (YoY)2461.03%
EBITD / Share (TTM)$-7.72
ROE (5Y Avg)-5564.42%
Operating Margin (TTM)-29.76%
Cash Flow / Share (Annual)$-22.92
P/B Ratio3.42x
P/B Ratio (Quarterly)2.28x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2.76x
Net Interest Coverage (TTM)-159.00x
ROA (TTM)-114.83%
EV / EBITDA (TTM)0.69x
EPS Incl Extra (Annual)$-32.15
Current Ratio (Annual)0.36x
Quick Ratio (Quarterly)2.60x
3-Month Avg Trading Volume0.03M
52-Week Price Return100.64%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.41
P/S Ratio (Annual)8.73x
Asset Turnover (Annual)0.42x
52-Week High$31.00
Operating Margin (5Y Avg)-4655.03%
EPS Excl Extra (Annual)$-32.15
Tangible BV CAGR (5Y)-65.38%
26-Week Price Return204.41%
Quick Ratio (Annual)0.33x
13-Week Price Return30.36%
Total Debt / Equity (Annual)2.00x
Current Ratio (Quarterly)2.76x
Enterprise Value$24.743
Asset Turnover (TTM)0.68x
Book Value / Share Growth (5Y)-69.76%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.39x
Pretax Margin (Annual)-662.26%
Cash / Share (Annual)$2.76
3-Month Return Std Dev84.31%
Gross Margin (5Y Avg)94.88%
Net Income / Employee (TTM)$-0
ROE (Last FY)-27540.00%
Net Interest Coverage (Annual)-50.33x
EPS Basic Excl Extra (Annual)$-32.15
P/FCF (TTM)10.29x
Receivables Turnover (TTM)3.10x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-10.46
Receivables Turnover (Annual)3.10x
ROI (TTM)-43.61%
P/S Ratio (TTM)4.38x
Pretax Margin (5Y Avg)-4484.31%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.01
Price vs S&P 500 (52W)66.00%
Year-to-Date Return43.50%
5-Day Price Return7.71%
EPS Normalized (Annual)$-32.15
ROA (5Y Avg)-222.13%
Net Profit Margin (Annual)-662.26%
Month-to-Date Return26.69%
Cash Flow / Share (TTM)$-2.16
EBITD / Share (Annual)$-31.95
Operating Margin (Annual)-501.02%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1891.63%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-10.46
P/B Ratio (Annual)241.99x
Inventory Turnover (TTM)0.39x
Pretax Margin (TTM)-28.85%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)27.98%
Beta0.74x
P/FCF (Annual)0.95x
Revenue / Share (TTM)$3.53
ROE (TTM)-43.61%
52-Week Low$2.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PTNPalatin Technologies, Inc. | 4.38x | 2461.03% | 97.83% | — | $22.07 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Palatin Technologies is a biopharmaceutical company developing first-in-class, receptor-specific medicines that modulate the melanocortin receptor system. The company targets diseases with unmet medical needs and significant commercial potential. Palatin operates as a focused life science business.